Eiry W. Roberts was named Chief Medical Officer of Neurocrine Biosciences Inc, effective September 28, 2026. As of November 6, 2026, Neurocrine Biosciences Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on September 28, 2026, naming 1 appointment (Form 8-K, September 28, 2026).
NEUROCRINE BIOSCIENCES INC named a new Chief Medical Officer on Sep 28. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Neurocrine Biosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Neurocrine Biosciences Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-09-28. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Neurocrine Biosciences Inc files it.
Also on the record for Neurocrine Biosciences Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5% of the class | 5%+ stakes | Source |
| October 15, 2026 | Stake report, Schedule 13G/A, by JPMORGAN CHASE & CO. | 5.2% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by JPMORGAN CHASE & CO. | 6.3% of the class | 5%+ stakes | Source |
| May 18, 2026 | Acquired Soleno Therapeutics, Inc. | $2.90B | Acquisition | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.23% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by JPMORGAN CHASE & CO. | 5.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Neurocrine Biosciences Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Neurocrine Biosciences Inc and the records around it.
Neurocrine Biosciences Inc elsewhere on the record
Companies that share a holder
- JPMORGAN CHASE & CO. also filed stake reports on 116 other companies: LEVI STRAUSS & CO (Nov 2026), Warner Music Group Corp. (Nov 2026), Andersen Group Inc. (Oct 2026)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Neurocrine Biosciences Inc
Get an email when Neurocrine Biosciences Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Neurocrine Biosciences Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Neurocrine Biosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neurocrine Biosciences Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-28 | In | Chief Medical Officer | 2026-09-28 | 8-K, 2026-09-28 |
Who leads Neurocrine Biosciences Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Eiry W. Roberts, appointed, effective 2026-09-28 (filed 2026-09-28).
New leaders reset buying decisions — get the Full Report on Neurocrine Biosciences Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at Neurocrine Biosciences Inc, with the record behind each one.
Find candidates like Chief Medical Officer at Neurocrine Biosciences IncEvery change, in the filing's words
Appointed: Eiry W. Roberts, Chief Medical Officer, effective 2026-09-28
On September 28, 2026, the Board of Directors (the "Board") of Neurocrine Biosciences, Inc. (the "Company") appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company's Chief Medical Officer, effective September 28, 2026 (the "Transition Date").
- On September 25, 2026, Dr. Keswani and the Board mutually agreed that Dr. Keswani's service as the Company's Chief Medical Officer would terminate as of September 25, 2026.
- In connection with Dr. Roberts' appointment as the Company's Chief Medical Officer, the Company will enter into an Amended and Restated Employment Agreement with Dr. Roberts (the "Employment Agreement"), to be effective as of the Transition Date.
- The Employment Agreement will amend and restate the amended and restated employment agreement that the Company previously entered into with Dr. Roberts on May 30, 2025, as it was previously amended on November 21, 2025.
- Pursuant to the Employment Agreement, Dr. Roberts will receive an annual base salary of $825,000 and will be eligible to receive an annual cash incentive bonus with a target bonus amount equal to 60% of her base pay earned for calendar year 2026.
- The Equity Grants will automatically be granted to Dr. Roberts on the date that is two business days following the filing of the Company's first quarterly report on Form 10-Q following the Transition Date, provided Dr. Roberts remains employed with the Company as of such date.
- The number of shares underlying the Equity Grants will be determined by reference to the price of the Company's common stock on the grant date, as further described in the Employment Agreement.
Tools for this story
Each opens in a new tab, filled in for Neurocrine Biosciences Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.